Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 18/20 | 0.78 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | NTRK3 | Q16288 | 3/20 | 0.47 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17110662 | 0.88 | NTRK1 (1.00) | NTRK1 | |
| SCHEMBL18779374 | 0.87 | NTRK1 (0.79) | NTRK1NTRK3NTRK2 | |
| SCHEMBL17110698 | 0.76 | NTRK1 (1.00) | NTRK1 | |
| SCHEMBL17110693 | 0.74 | NTRK1 (1.00) | NTRK1 | |
| SCHEMBL16585348 | 0.73 | NTRK1 (0.85) | NTRK1NTRK3NTRK2 | |
| SCHEMBL16586807 | 0.72 | NTRK1 (1.00) | NTRK1NTRK3NTRK2 | |
| SCHEMBL18779371 | 0.71 | NTRK1 (0.78) | NTRK1NTRK3 | |
| SCHEMBL17110742 | 0.70 | NTRK1 (1.00) | NTRK1 | |
| SCHEMBL17110700 | 0.70 | NTRK1 (0.73) | NTRK1 | |
| SCHEMBL17110701 | 0.70 | NTRK1 (1.00) | NTRK1NTRK3NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9815846-B2 | TrkA kinase inhibitors, compositions and methods thereof | MERCK SHARP & DOHME CORP. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170114071-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114071-A1 | TRKA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | NGFR, NGF, NTRK1 | NTRK1 3/4885ADORA2A 3962/4885ADORA1 4320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.